

Ducray Densiage Redensifying Hair Care to Launch in March

Ducray Laboratoires Dermatologiques introduces the Densiage Redensifying hair care line for patients with thin and brittle hair. This line consists of 4 products: the Densiage Redensifying Shampoo to noticeably improve hair quality; the Densiage Redensifying Conditioner to provide detangling benefits and leave hair softer; the Densiage Redensifying Serum to promote development of thicker denser hair with more volume; and the Densiage Dietary Supplement for Aging Hair to provide nutrients to maintain hair density and protect against signs of aging. The line will be available in March 2019. For more information, visit www.ducray.com.

Revance Announces Phase 3 Results for Neuromodulator DaxibotulinumtoxinA

Revance Therapeutics, Inc, works to submit a Biologics License Application with the US Food and Drug Administration in the first half of 2019 for its injectable neuromodulator daxibotulinumtoxinA (RT002) following results from a phase 3 open-label, long-term safety study on treating moderate to severe glabellar (frown) lines. Participants received up to 3 treatments of RT002 and were followed for more than 1.5 years. Overall, the safety findings were consistent with the known safety profiles for currently available neuromodulators in aesthetics. Measuring duration of effect, the median time to return to baseline glabellar line severity was 28 weeks. The median time to loss of none or mild wrinkle severity was 24 weeks. The results demonstrate that RT002, utilizing proprietary stabilizing excipient peptide technology in its formulation, produces long duration and high response rates and is well tolerated over successive treatments. For more information, visit www.revance.com.

SNA-120 Demonstrates Potential for Psoriasis in Phase 2b Trial

Sienna Biopharmaceuticals announces results of a phase 2b study of the tropomyosin receptor kinase A (TrkA) inhibitor SNA-120 (pegcantratinib) for mild to moderate psoriasis, with itch as the primary end point. SNA-120 blocks nerve growth factor signaling, which plays an important role in the pathogenesis of psoriasis and itch. Participants (N=208) achieved 58% improvement in itch from baseline; efficacy results indicated 75% reduction in psoriasis area and severity index score from baseline in 27% of participants versus 13% with vehicle, and 29% of participants achieved 2-grade improvement in investigator global assessment versus 13% with vehicle. These results demonstrate the potential of SNA-120 as a topical nonsteroidal treatment of psoriasis. Phase 3 studies for psoriasis will begin in the second half of 2019. For more information, visit www.siennabio.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@mdedge.com.